Biocon Ltd, India's leading biotechnology enterprise has notified that NeoBiocon and Abraxis BioScience have launched Arbaxan (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the UAE market for the treatment of breast cancer.

NeoBiocon is a joint venture between Dr. B R Shetty, MD & CEO of Abu Dhabi based Company Neopharma and Kiran Mazumdar-Shaw, Chairman & MD of India's biotechnology major Biocon Ltd. 

India-based Matrix Laboratories, a subsidiary of US-based Mylan Inc, has signed an agreement with Aspen Pharmacare Holdings Ltd of South Africa to sell 50 percent stake in Fine Chemicals Corporation (Proprietary) Limited (FCC) of South Africa in favour of Aspen.

While in turn, Aspen would sell its 50% stake in India's Astrix Laboratories Ltd to Matrix. However, Aspen will retain a shareholding in Astrix through a B-share.

Drug maker, Aurobindo Pharma has informed that it has secured approval from US Food and Drug Administration (USFDA) for marketing Fluconazole drug.

Under the approval, the company will market and distribute the drug in the strengths of 50 mg, 100 mg, 150 mg and 200 mg respectively. 

Fluconazole is used to treat fungal infections - yeast infections, urinary tract infections, peritonitis, pneumonia, AIDS cryptoccal infections. The drug would be available in both tablet and oral dosage form.

World’s second major drug maker, GlaxoSmithKline (GSK) has made announcement that the company is proposing to build a new manufacturing production line in Nashik, Maharashtra with the aim to produce 300 million tablets of albendazole per year for curing Lymphatic Filariasis (LF).

Lymphatic Filariasis (Philariasis) is a parasitic and infectious tropical disease that is caused by thread-like parasitic worms, of the type filarial nematode.

Dr Reddy's Laboratories Ltd has informed that it has received approval from the U.S. Food and Drug Administration to sell its anti-convulsant drug primidone tablets in the strength of 50 mg and 250mg in the market. 

Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.

The report stated that company is allowed to sell the drug in the United States in tablet forms of 50 milligram and 250 milligram strengths.

Strides Arcolab, one of the leading Indian pharmaceutical company, has informed that the U.S. Food and Drug Administration (USFDA) had approved its oral dosage manufacturing unit in Bangalore.

Following this approval, Strides will be able to export drugs with regulatory approval to the United States.

Recently, the company has secured two abbreviated new drug application (ANDA) approvals for Dexamethasone injection in the strength of 4mg/ml and Dexamethasone Sodium Phosphate injection, in the strength of 10 mg /ml.